Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys
- PMID: 11823518
- DOI: 10.4049/jimmunol.168.4.1847
Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys
Abstract
Since virus-specific CTL play a central role in containing HIV replication, a candidate AIDS vaccine should generate virus-specific CTL responses. In this study, the ability of a recombinant canarypox virus expressing SIV Gag-Pol-Env (ALVAC/SIV gag-pol-env) was assessed for its ability to elicit both dominant and subdominant epitope-specific CTL responses in rhesus monkeys. Following a series of five immunizations, memory CTL responses specific for a dominant Gag epitope could be demonstrated in the peripheral blood of vaccinated monkeys. Memory CTL responses to a subdominant Pol epitope were undetectable in these animals. Following challenge with SIVmac251, the experimentally vaccinated animals developed high frequency CTL responses specific for the dominant Gag epitope that emerged in temporal association with the early containment of viral replication. Interestingly, the experimentally vaccinated, but not the control vaccinated animals, developed CTL responses to the subdominant Pol epitope that were detectable only after containment of early viremia. Thus, recombinant canarypox vaccination elicited low frequency, but durable memory CTL populations. The temporal association of the emergence of the dominant epitope-specific response with early viral containment following challenge suggests that this immune response played a role in the accelerated clearing of early viremia in these animals. The later emerging CTL response specific for the subdominant epitope may contribute to the control of viral replication in the setting of chronic infection.
Similar articles
-
Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.J Immunol. 2002 Nov 1;169(9):4778-87. doi: 10.4049/jimmunol.169.9.4778. J Immunol. 2002. PMID: 12391187
-
Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.J Virol. 2000 Aug;74(16):7485-95. doi: 10.1128/jvi.74.16.7485-7495.2000. J Virol. 2000. PMID: 10906202 Free PMC article.
-
A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.J Immunol. 2003 Apr 15;170(8):4281-9. doi: 10.4049/jimmunol.170.8.4281. J Immunol. 2003. PMID: 12682263
-
Cytotoxic T lymphocytes specific for the simian immunodeficiency virus.Immunol Rev. 1999 Aug;170:127-34. doi: 10.1111/j.1600-065x.1999.tb01334.x. Immunol Rev. 1999. PMID: 10566147 Review.
-
Virus replication and evolution drive the kinetics and specificity of SIV-specific cytotoxic T lymphocytes.Immunol Rev. 2001 Oct;183:109-14. doi: 10.1034/j.1600-065x.2001.1830109.x. Immunol Rev. 2001. PMID: 11782251 Review.
Cited by
-
Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses.Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11088-93. doi: 10.1073/pnas.0401954101. Epub 2004 Jul 16. Proc Natl Acad Sci U S A. 2004. PMID: 15258286 Free PMC article.
-
Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV.J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):124-34. doi: 10.1097/00126334-200502010-00002. J Acquir Immune Defic Syndr. 2005. PMID: 15671796 Free PMC article.
-
Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection.J Virol. 2002 Jun;76(12):6376-81. doi: 10.1128/jvi.76.12.6376-6381.2002. J Virol. 2002. PMID: 12021371 Free PMC article.
-
Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.J Virol. 2006 Apr;80(8):3732-42. doi: 10.1128/JVI.80.8.3732-3742.2006. J Virol. 2006. PMID: 16571790 Free PMC article.
-
Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus.Virology. 2007 Jan 20;357(2):199-214. doi: 10.1016/j.virol.2006.08.007. Epub 2006 Sep 7. Virology. 2007. PMID: 16962628 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources